Yarger Wealth Strategies LLC Has $299,000 Stake in Abbott Laboratories (NYSE:ABT)

Yarger Wealth Strategies LLC reduced its holdings in Abbott Laboratories (NYSE:ABT) by 3.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,646 shares of the healthcare product maker’s stock after selling 96 shares during the period. Yarger Wealth Strategies LLC’s holdings in Abbott Laboratories were worth $299,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Woodstock Corp raised its position in shares of Abbott Laboratories by 0.7% during the 4th quarter. Woodstock Corp now owns 132,469 shares of the healthcare product maker’s stock valued at $14,984,000 after acquiring an additional 940 shares during the last quarter. Goldstone Financial Group LLC increased its holdings in Abbott Laboratories by 1.0% in the fourth quarter. Goldstone Financial Group LLC now owns 9,947 shares of the healthcare product maker’s stock valued at $1,125,000 after purchasing an additional 99 shares during the last quarter. Capital Planning LLC lifted its stake in Abbott Laboratories by 1.2% in the fourth quarter. Capital Planning LLC now owns 8,673 shares of the healthcare product maker’s stock valued at $981,000 after buying an additional 100 shares during the period. Decker Retirement Planning Inc. bought a new position in Abbott Laboratories during the fourth quarter worth about $2,275,000. Finally, Empirical Asset Management LLC grew its position in shares of Abbott Laboratories by 238.2% during the 4th quarter. Empirical Asset Management LLC now owns 47,791 shares of the healthcare product maker’s stock worth $5,406,000 after buying an additional 33,659 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Up 2.5 %

NYSE ABT opened at $113.85 on Friday. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $121.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock’s 50 day moving average price is $115.02 and its two-hundred day moving average price is $112.65. The stock has a market capitalization of $197.47 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.40 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The business had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $10.55 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. As a group, analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a $0.59 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 annualized dividend and a dividend yield of 2.07%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 66.87%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABT shares. Oppenheimer began coverage on shares of Abbott Laboratories in a research report on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price target on the stock. Jefferies Financial Group increased their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a report on Thursday, October 17th. Sanford C. Bernstein boosted their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Royal Bank of Canada lifted their target price on Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Piper Sandler increased their price target on Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $131.57.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.